157 related articles for article (PubMed ID: 20921950)
1. Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.
Hennenberg M; Trebicka J; Kohistani Z; Stark C; Nischalke HD; Krämer B; Körner C; Klein S; Granzow M; Fischer HP; Heller J; Sauerbruch T
Lab Invest; 2011 Feb; 91(2):241-51. PubMed ID: 20921950
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.
Hennenberg M; Trebicka J; Stark C; Kohistani AZ; Heller J; Sauerbruch T
Br J Pharmacol; 2009 May; 157(2):258-70. PubMed ID: 19338580
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
Mejias M; Garcia-Pras E; Tiani C; Miquel R; Bosch J; Fernandez M
Hepatology; 2009 Apr; 49(4):1245-56. PubMed ID: 19137587
[TBL] [Abstract][Full Text] [Related]
4. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.
Zhou Q; Hennenberg M; Trebicka J; Jochem K; Leifeld L; Biecker E; Sauerbruch T; Heller J
Gut; 2006 Sep; 55(9):1296-305. PubMed ID: 16492715
[TBL] [Abstract][Full Text] [Related]
5. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
Wang Y; Gao J; Zhang D; Zhang J; Ma J; Jiang H
J Hepatol; 2010 Jul; 53(1):132-44. PubMed ID: 20447716
[TBL] [Abstract][Full Text] [Related]
6. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.
Thabut D; Routray C; Lomberk G; Shergill U; Glaser K; Huebert R; Patel L; Masyuk T; Blechacz B; Vercnocke A; Ritman E; Ehman R; Urrutia R; Shah V
Hepatology; 2011 Aug; 54(2):573-85. PubMed ID: 21567441
[TBL] [Abstract][Full Text] [Related]
7. Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study.
Wei L; Yang J; Wang M; Xu SN; Liang HM; Zhou Q
Int J Mol Med; 2014 Nov; 34(5):1257-67. PubMed ID: 25174394
[TBL] [Abstract][Full Text] [Related]
8. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
9. The Salvia miltiorrhiza monomer IH764-3 induces apoptosis of hepatic stellate cells in vivo in a bile duct ligation-induced model of liver fibrosis.
Liu L; Wei J; Huo X; Fang S; Yao D; Gao J; Jiang H; Zhang X
Mol Med Rep; 2012 Dec; 6(6):1231-8. PubMed ID: 22971838
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
Reiberger T; Angermayr B; Schwabl P; Rohr-Udilova N; Mitterhauser M; Gangl A; Peck-Radosavljevic M
J Hepatol; 2009 Nov; 51(5):865-73. PubMed ID: 19726100
[TBL] [Abstract][Full Text] [Related]
11. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
12. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.
Yang YY; Huang YT; Lee KC; Lee FY; Lee TY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2009 Jan; 116(1):71-9. PubMed ID: 18479249
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells.
Trebicka J; Hennenberg M; Odenthal M; Shir K; Klein S; Granzow M; Vogt A; Dienes HP; Lammert F; Reichen J; Heller J; Sauerbruch T
J Hepatol; 2010 Oct; 53(4):702-12. PubMed ID: 20633948
[TBL] [Abstract][Full Text] [Related]
14. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats.
D'Amico M; Mejías M; García-Pras E; Abraldes JG; García-Pagán JC; Fernández M; Bosch J
Am J Physiol Gastrointest Liver Physiol; 2012 May; 302(10):G1191-8. PubMed ID: 22403792
[TBL] [Abstract][Full Text] [Related]
15. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension.
Jalan R; De Chiara F; Balasubramaniyan V; Andreola F; Khetan V; Malago M; Pinzani M; Mookerjee RP; Rombouts K
J Hepatol; 2016 Apr; 64(4):823-33. PubMed ID: 26654994
[TBL] [Abstract][Full Text] [Related]
16. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
Klein S; Van Beuge MM; Granzow M; Beljaars L; Schierwagen R; Kilic S; Heidari I; Huss S; Sauerbruch T; Poelstra K; Trebicka J
J Hepatol; 2012 Dec; 57(6):1220-7. PubMed ID: 22878469
[TBL] [Abstract][Full Text] [Related]
17. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
18. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
19. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Pinter M; Sieghart W; Reiberger T; Rohr-Udilova N; Ferlitsch A; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2012 Jan; 35(1):83-91. PubMed ID: 22032637
[TBL] [Abstract][Full Text] [Related]
20. Increased contractility of hepatic stellate cells in cirrhosis is mediated by enhanced Ca2+-dependent and Ca2+-sensitization pathways.
Iizuka M; Murata T; Hori M; Ozaki H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1010-21. PubMed ID: 21393429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
